MU-D201
/ Medpacto
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 01, 2020
MedPacto’s oncology pipeline for blood cancer wins EU patent
(Korea Biomedical Review)
- "MedPacto said...that it has obtained a European patent for a pharmaceutical composition to prevent and treat blood cancer...The company plans to apply the patent to the development of MU-D201, a follow-up pipeline of new anticancer drug Vactosertib...MedPacto confirmed that MU-D201 inhibits DRAK2 and suppresses growth and metastasis of cancer and has an anticancer effect in a preclinical study....MedPacto won the same patent rights in several countries, including Korea, Japan and the U.S., before the commercialization of MU-D201."
Patent • Preclinical • Oncology
1 to 1
Of
1
Go to page
1